Security key
36322Q206
Damora Therapeutics, Inc. - Common Stock (DMRA)
CUSIP: 36322Q206
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 142,568
- Total 13F value
- $441,959
- Share change
- +506
- SEC-reported price per share
- $3.10
- Number of holders
- 10
- Value change
- +$1,278
- Number of buys
- 4
- Number of sells
- 3
- Shares outstanding
- 61,638,745
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
10
Top holders
10
DMRA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2025
Damora Therapeutics, Inc. SEC filings
Damora Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 36322Q206
Recent filing periods:
Ownership snapshot
Top reported holders of DMRA - Damora Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
0/15
Latest evidence
31 Dec 2024
3/4/5
13F
Highest disclosed value: $1,132,781
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC has the largest disclosed position value at $1.13M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Disclosed position value
Top 5
ORBIMED ADVISORS LLC
$1.13M
Novo Holdings A/S
$464.6K
Jonathan Freve
$75K
RENAISSANCE TECHNOLOGIES LLC
$70K
Squarepoint Ops LLC
$59.1K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,132,781
1,510,375 shares
|
— | 15 Aug 2023 |
| Novo Holdings A/S |
13F
Company
|
—
denominator unverified
|
$464,595
99,913 shares
|
— | 31 Dec 2024 |
| Jonathan Freve |
3/4/5
Chief Financial Officer
|
—
mixed-class rows
|
$75,000
215,000 shares
mixed-class rows
|
— | 03 Jan 2024 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
—
denominator unverified
|
$69,955
15,044 shares
|
— | 31 Dec 2024 |
| Squarepoint Ops LLC |
13F
Company
|
—
denominator unverified
|
$59,123
12,701 shares
|
— | 31 Dec 2024 |
| UBS Group AG |
13F
Company
|
—
denominator unverified
|
$57,972
12,467 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
142,568
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q2 2026 Across Filers
Q2 2026 holders
101
Q1 2025 holders
10
Holder diff
-91
| Investor | Q2 2026 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q2 2026 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend